Evotec SE
EVT
Rank in Stocks
#10943
Evotec SE functions as a global collaborator, aiding the pharmaceutical and... Evotec SE functions as a global collaborator, aiding the pharmaceutical and biotechnology industries in the identification and progression of novel drug candidates. The firm is actively engaged in advancing medicinal products designed to treat a diverse array of health challenges, including diabetes and its related complications, various fibrotic conditions, infectious diseases, disorders of the central nervous system, oncological conditions, pain management, inflammatory and immunological ailments, rare diseases, respiratory illnesses, and women's health concerns. Evotec SE has forged partnerships with a number of significant players in the sector, such as Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. The company, initially incorporated as Evotec AG in 1993, underwent a name change to Evotec SE in April 2019 and maintains its corporate headquarters in Hamburg, Germany.
Share Price
$3.53
Last synced: 2026-11-09
Market Cap
$626.22M
Change (1 day)
-0.03%
Change (1 year)
-40.44%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Evotec SE (EVT)
Category
Healthcare
EPS for Evotec SE (EVT)
EPS as of September 2026 TTM: $-1.14
According to Evotec SE's latest financial reports, its current EPS (TTM) is $-1.14. At the end of 2025 the company had an EPS of $-0.68, an increase over its 2024 EPS of $-1.16.
EPS history for Evotec SE from 2001 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.14 | 67.28% |
| 2025 | $-0.68 | -41.08% |
| 2024 | $-1.16 | 122.29% |
| 2023 | $-0.52 | -51.07% |
| 2022 | $-1.06 | -171.83% |
| 2021 | $1.48 | 2,935.52% |
| 2020 | $0.05 | -82.64% |
| 2019 | $0.28 | -57.18% |
| 2018 | $0.66 | 241.15% |
| 2017 | $0.19 | -8.75% |
| 2016 | $0.21 | 49.01% |
| 2015 | $0.14 | -319.94% |
| 2014 | $-0.06 | -77.77% |
| 2013 | $-0.29 | -1,193.94% |
| 2012 | $0.03 | -66.02% |
| 2011 | $0.08 | 93.77% |
| 2010 | $0.04 | -106.50% |
| 2009 | $-0.62 | -46.04% |
| 2008 | $-1.14 | 388.58% |
| 2007 | $-0.23 | -83.84% |
| 2006 | $-1.45 | -2.00% |
| 2005 | $-1.48 | -19.91% |
| 2004 | $-1.84 | -96.04% |
| 2003 | $-46.61 | 11.12% |
| 2002 | $-41.94 | 15.71% |
| 2001 | $-36.25 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | -671.55% |
DE
|
|
| $6.08 | -634.29% |
DE
|
|
| $1.55 | -236.32% |
JP
|
|
| $3.66 | -421.76% |
CH
|
|
| $0.45 | -139.56% |
IL
|
Questions about Evotec SE's earnings per share (EPS)
What is Evotec SE's earnings per share (EPS)?
Evotec SE's earnings per share (EPS) over the last twelve months is $-1.14, as of Sep 2026.
What was Evotec SE's earnings per share (EPS) in 2025?
In 2025, Evotec SE's earnings per share (EPS) was $-0.68, compared with $-1.16 in 2024.
How has Evotec SE's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Evotec SE's earnings per share (EPS) was highest in 2021 ($1.48) and lowest in 2024 ($-1.16).
How does Evotec SE's earnings per share (EPS) compare with similar companies?
Evotec SE's earnings per share (EPS) ($-1.14) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.